^
Association details:
| Biomarker: | EGFR mutation + KRAS mutation |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P37.05 - Prognostic Characteristics and Immunotherapy Response of Non-Squamous NSCLC Patients with KRAS Mutation in East Asian Populations
Published date:
01/12/2021
Excerpt:
Among the patients with Kras mutations, 8 (3.4%) patients had tumors with concomitant Kras- and EGFR mutations, including 4 deletion-19, 2 L858R, one G709V, and one G719S+E709A. Of them, 6 patients received EGFR TKI treatment (4 gefitinib and 2 erlotinib). The treatment responses were 3 partial response, 1 stable disease, and 2 progressive disease.
